The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2018 | Results from the PACIFIC study: durvalumab with chemoradiation for the treatment of NSCLC
Immunotherapy has become revolutionary in the treatments of a range of malignancies, with non-small cell lung cancer (NSCLC) being one disease that is receiving significant attention. Discussing the results from the PACIFIC study (NCT02125461) is Solange Peters, MD, PhD, from the University of Lausanne, Lausanne, Switzerland, who outlines the promising results from the trial investigating the monoclonal antibody therapy durvalumab for patients with stage III NSCLC. Speaking from the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland, Dr Peters mentions the highlights of the trial, including durvalumab delivering 17 months of progression-free survival that has previously been unmet with current treatments. Improved quality of life and survival rates show that immunotherapy combined with chemoradiation therapy is the optimal treatment option for NSCLC.
